Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?

Neural mechanisms linked to treatment outcomes and recovery in substance-related and addictive disorders

“…These findings raise the intriguing and currently speculative notion that interventions promoting synaptic density (e.g., ketamine) may have potential treatment utility, and perhaps particularly in individuals with co-occurring depression (Angarita et al. 2021 ). Regarding subcortical regions such as the striatum, amygdala or hippocampus, there are insufficient studies to draw strong conclusions regarding treatment-GMV relationships, with some studies suggesting different directions of associations when linking GMVs to treatment outcomes (Moeller and Paulus 2018 ).…”

“…Several recent articles have reviewed novel pharmacotherapies for cocaine use disorder (Angarita et al. 2021 ; Hadizadeh, Flores, Mayerson, et al. 2022 ; Hadizadeh, Flores, Nunes, et al.…”

Dopamine D3/D2 Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders

“…To further complicate matters, substance use disorders (SUDs) frequently occur with affective disorders, including anxiety, major depressive disorder, and bipolar disorder. Such dual disorders have also increased during the COVID-19 pandemic − and are particularly difficult to treat when comorbid with psychostimulant use disorders (PSUD), , for which there is currently no FDA-approved pharmacotherapeutic.…”

The incubation of cocaine craving is dissociated from changes in glial cell markers within prefrontal cortex and nucleus accumbens of rats

“…Finally, microglial cell activation has been linked to depression, a common disorder co-morbid with SUDs [e.g., 25 - 27 ]. Indeed, alcohol, methamphetamine, depression and stress all enhance innate immune gene induction within microglia [ 14 ].…”